微脉冲二极管激光治疗难治性青光眼。

Moctar Issiaka , Khalil Zrikem , Adil Mchachi , Leila Benhmidoune , Rayad Rachid , Mohamed EL. Belhadji , Abdoul Salam Youssoufou Souley , Abdou Amza
{"title":"微脉冲二极管激光治疗难治性青光眼。","authors":"Moctar Issiaka ,&nbsp;Khalil Zrikem ,&nbsp;Adil Mchachi ,&nbsp;Leila Benhmidoune ,&nbsp;Rayad Rachid ,&nbsp;Mohamed EL. Belhadji ,&nbsp;Abdoul Salam Youssoufou Souley ,&nbsp;Abdou Amza","doi":"10.1016/j.aopr.2022.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Description of safety and efficacy of micropulse Transscleral cyclophotocoagulation as a treatment option for refractory glaucoma.</p></div><div><h3>Methods</h3><p>This is a prospective study including 39 eyes of 31 patients followed for refractory glaucoma, who benefited from transscleral cyclophotocoagulation using a microplused laser. The main indication for the procedure was increased ocular pressure refractory to quadritherapy in various types of glaucoma. The patients were treated using iridex Cyclo G6 laser with a Micropulse P3 infrared probe with a wavelength of 810 ​nm. The parameters for the procedure were a duration of 90 ​s per hemisphere with a power of 2000 mW and an energy of 180 ​J. Both the upper and lower hemispheres were treated in the same procedure, sparing the 3 o'clock and 9 o'clock meridians, and all the patients benefited from a single treatment session. The following parameters were evaluated: ocular pain and overall tolerance; visual acuity; and the evolution of IOP postoperatively up to 9 months.</p></div><div><h3>Results</h3><p>The glaucoma subtypes treated are as follows: primary open-angle glaucoma (n ​= ​05), chronic angle-closure glaucoma (n ​= ​13), neovascular glaucoma (n ​= ​07), aphakic glaucoma (n ​= ​06), malignant glaucoma (n ​= ​04), post-traumatic angle recession (n ​= ​02), and inflammatory glaucoma (n ​= ​02). The mean pre-operative intraocular pressure was 42.3 ​± ​5.2 ​mmHg and the mean post-operative intraocular pressure at 9 months was 16.9 ​± ​1.9 ​mmHg. The reduction in IOP was 49.9%. The average number of intraocular pressure-lowering medications used prior to surgery was four, and the average number of medications used at the 9-month post-operative visit was 2.0 ​± ​1.2 (70.3% of patients were on dual therapy). The overall success rate was 60.5%.</p></div><div><h3>Conclusions</h3><p>Micropulse transscleral cyclophotocoagulation appears to be a safe and efficient treatment for refractory glaucoma. Its indications should therefore be broadened and proposed early in various situations.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/85/main.PMC10577867.pdf","citationCount":"1","resultStr":"{\"title\":\"Micropulse diode laser therapy in refractory glaucoma\",\"authors\":\"Moctar Issiaka ,&nbsp;Khalil Zrikem ,&nbsp;Adil Mchachi ,&nbsp;Leila Benhmidoune ,&nbsp;Rayad Rachid ,&nbsp;Mohamed EL. Belhadji ,&nbsp;Abdoul Salam Youssoufou Souley ,&nbsp;Abdou Amza\",\"doi\":\"10.1016/j.aopr.2022.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>Description of safety and efficacy of micropulse Transscleral cyclophotocoagulation as a treatment option for refractory glaucoma.</p></div><div><h3>Methods</h3><p>This is a prospective study including 39 eyes of 31 patients followed for refractory glaucoma, who benefited from transscleral cyclophotocoagulation using a microplused laser. The main indication for the procedure was increased ocular pressure refractory to quadritherapy in various types of glaucoma. The patients were treated using iridex Cyclo G6 laser with a Micropulse P3 infrared probe with a wavelength of 810 ​nm. The parameters for the procedure were a duration of 90 ​s per hemisphere with a power of 2000 mW and an energy of 180 ​J. Both the upper and lower hemispheres were treated in the same procedure, sparing the 3 o'clock and 9 o'clock meridians, and all the patients benefited from a single treatment session. The following parameters were evaluated: ocular pain and overall tolerance; visual acuity; and the evolution of IOP postoperatively up to 9 months.</p></div><div><h3>Results</h3><p>The glaucoma subtypes treated are as follows: primary open-angle glaucoma (n ​= ​05), chronic angle-closure glaucoma (n ​= ​13), neovascular glaucoma (n ​= ​07), aphakic glaucoma (n ​= ​06), malignant glaucoma (n ​= ​04), post-traumatic angle recession (n ​= ​02), and inflammatory glaucoma (n ​= ​02). The mean pre-operative intraocular pressure was 42.3 ​± ​5.2 ​mmHg and the mean post-operative intraocular pressure at 9 months was 16.9 ​± ​1.9 ​mmHg. The reduction in IOP was 49.9%. The average number of intraocular pressure-lowering medications used prior to surgery was four, and the average number of medications used at the 9-month post-operative visit was 2.0 ​± ​1.2 (70.3% of patients were on dual therapy). The overall success rate was 60.5%.</p></div><div><h3>Conclusions</h3><p>Micropulse transscleral cyclophotocoagulation appears to be a safe and efficient treatment for refractory glaucoma. Its indications should therefore be broadened and proposed early in various situations.</p></div>\",\"PeriodicalId\":72103,\"journal\":{\"name\":\"Advances in ophthalmology practice and research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/85/main.PMC10577867.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in ophthalmology practice and research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667376222000713\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in ophthalmology practice and research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667376222000713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

目的:描述微脉冲经巩膜睫状体光凝治疗难治性青光眼的安全性和有效性。方法:这是一项前瞻性研究,包括31例难治性青光眼患者中的39眼,这些患者受益于使用微激光的经巩膜睫状体光凝。该手术的主要适应症是对各种类型的青光眼进行四次治疗后出现的眼压升高。患者使用彩虹色Cyclo G6激光器和波长为810的微脉冲P3红外探头进行治疗​nm。手术参数为90​s,功率为2000mW,能量为180​J.上半球和下半球在相同的程序中接受治疗,保留了3点钟和9点钟经脉,所有患者都从一次治疗中受益。评估了以下参数:眼部疼痛和总体耐受性;视力;术后9个月眼压的变化。结果:治疗的青光眼亚型如下:原发性开角型青光眼(n​=​05)、慢性闭角型青光眼(n​=​13) ,新生血管性青光眼(n​=​07)、无晶状体青光眼(n​=​06)、恶性青光眼(n​=​04),创伤后角衰退(n​=​02)和炎症性青光眼(n​=​02)。术前平均眼压为42.3​±​5.2​mmHg,术后9个月平均眼压为16.9​±​1.9​mmHg。眼压降低了49.9%。手术前使用的平均眼压降低药物数量为4种,术后9个月访视时使用的平均药物数量为2.0​±​1.2(70.3%的患者接受双重治疗)。总的成功率为60.5%。结论:微脉冲经巩膜睫状体光凝治疗难治性青光眼是一种安全有效的治疗方法。因此,应在各种情况下尽早扩大和提出其指示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Micropulse diode laser therapy in refractory glaucoma

Purpose

Description of safety and efficacy of micropulse Transscleral cyclophotocoagulation as a treatment option for refractory glaucoma.

Methods

This is a prospective study including 39 eyes of 31 patients followed for refractory glaucoma, who benefited from transscleral cyclophotocoagulation using a microplused laser. The main indication for the procedure was increased ocular pressure refractory to quadritherapy in various types of glaucoma. The patients were treated using iridex Cyclo G6 laser with a Micropulse P3 infrared probe with a wavelength of 810 ​nm. The parameters for the procedure were a duration of 90 ​s per hemisphere with a power of 2000 mW and an energy of 180 ​J. Both the upper and lower hemispheres were treated in the same procedure, sparing the 3 o'clock and 9 o'clock meridians, and all the patients benefited from a single treatment session. The following parameters were evaluated: ocular pain and overall tolerance; visual acuity; and the evolution of IOP postoperatively up to 9 months.

Results

The glaucoma subtypes treated are as follows: primary open-angle glaucoma (n ​= ​05), chronic angle-closure glaucoma (n ​= ​13), neovascular glaucoma (n ​= ​07), aphakic glaucoma (n ​= ​06), malignant glaucoma (n ​= ​04), post-traumatic angle recession (n ​= ​02), and inflammatory glaucoma (n ​= ​02). The mean pre-operative intraocular pressure was 42.3 ​± ​5.2 ​mmHg and the mean post-operative intraocular pressure at 9 months was 16.9 ​± ​1.9 ​mmHg. The reduction in IOP was 49.9%. The average number of intraocular pressure-lowering medications used prior to surgery was four, and the average number of medications used at the 9-month post-operative visit was 2.0 ​± ​1.2 (70.3% of patients were on dual therapy). The overall success rate was 60.5%.

Conclusions

Micropulse transscleral cyclophotocoagulation appears to be a safe and efficient treatment for refractory glaucoma. Its indications should therefore be broadened and proposed early in various situations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Global research trends in the treatment of squamous cell carcinoma over the past decade: A bibliometric analysis Understanding parental hurdles in accessing strabismus treatment Research progress on the impact of cataract surgery on corneal endothelial cells Editorial Board TOC
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1